Global X Genomics & Biotechnology ETF
GNOM
10 hedge funds and large institutions have $13M invested in Global X Genomics & Biotechnology ETF in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 6 → 10 (+4)
32% more capital invested
Capital invested by funds: $9.83M → $13M (+$3.19M)
4.22% less ownership
Funds ownership: 68.34% → 64.12% (-4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$438K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$180K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$48.9K |
| 4 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$8.93K |
| 5 |
AA
Advisory Alpha
Holland,
Michigan
|
+$2.18K |
Top Sellers
GNOM Hedge Fund Activity: Q4 2019 in Review
10 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q4 2019, worth a combined $13M — up 32% from $9.83M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GNOM positions and 0 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $438K.
- 10 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q4 2019, up from 6 in Q3 2019.
- Funds reported $13M of Global X Genomics & Biotechnology ETF stock for Q4 2019, up 32% quarter-over-quarter.
- 4 funds opened new Global X Genomics & Biotechnology ETF positions in Q4 2019 and 0 closed out, a net change of +4 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q4 2019 was Jane Street, an estimated $438K added.
Based on aggregated 13F filings for Q4 2019.